Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, Texas, USA.
Endocr Pract. 2010 May-Jun;16(3):449-51. doi: 10.4158/EP09304.CR.
To alert clinicians about the risk of vasculitis and cross-reactivity of antithyroid medication.
We describe the clinical course and medical management of the study patient.
A 25-year-old woman with hyperthyroidism developed antineutrophil cytoplasmic antibody-positive vasculitis after 15 months of propylthiouracil therapy. Her condition improved when propylthiouracil was withdrawn, but recurred when she was prescribed methimazole. Propylthiouracil and methimazole are commonly used antithyroid medications, and propylthiouracil is a well-recognized cause of drug-induced vasculitis. Cross-reactivity between the 2 drugs is likely, but it has not been reported previously with regard to vasculitis. Many patients with propylthiouracil-induced vasculitis have been switched to methimazole.
Awareness of this rare, but potentially serious, adverse drug reaction is important because prompt discontinuation of medication is essential. Cross-reactivity between propylthiouracil and methimazole must be considered when selecting alternative therapies.
提醒临床医生注意抗甲状腺药物的血管炎和交叉反应风险。
我们描述了研究患者的临床经过和医学管理。
一名 25 岁女性,甲亢,用丙硫氧嘧啶治疗 15 个月后发生抗中性粒细胞胞浆抗体阳性血管炎。停用丙硫氧嘧啶后病情改善,但改用甲巯咪唑后再次发作。丙硫氧嘧啶和甲巯咪唑是常用的抗甲状腺药物,丙硫氧嘧啶是公认的药物诱导血管炎的原因。这两种药物之间可能存在交叉反应,但以前没有报道过与血管炎有关。许多丙硫氧嘧啶诱导血管炎患者已改用甲巯咪唑。
认识到这种罕见但可能严重的药物不良反应很重要,因为及时停药是至关重要的。在选择替代疗法时,必须考虑丙硫氧嘧啶和甲巯咪唑之间的交叉反应。